ProfileGDS5678 / 1425034_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 65% 64% 64% 61% 63% 67% 67% 64% 62% 62% 64% 62% 65% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.9684565
GSM967853U87-EV human glioblastoma xenograft - Control 23.808464
GSM967854U87-EV human glioblastoma xenograft - Control 33.8083264
GSM967855U87-EV human glioblastoma xenograft - Control 43.6136361
GSM967856U87-EV human glioblastoma xenograft - Control 53.7001463
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0639767
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.152167
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.8051864
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7214262
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.71162
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8063564
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6901962
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9319265
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8071764